Management of Traumatic Intracranial Hemorrhage on Anticoagulant Regime: A Literature Review

Tedy Apriawan¹,², Ade Anugrah Kartosen¹,², Ahmad ZS Ishlahy¹,², Endang Pati Broto¹,², Hana Ranu Herjuna¹,², Khrisna Rangga Permana¹,², Rizki Meizikri¹,², Shaleh Drehem¹,², Abdul Hafid Bajamal¹,²

¹Neurosurgery Department, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia
²Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
Corresponding author: Rizki Meizikri (rizkimz@gmail.com)

ABSTRACT

Keywords: oral anticoagulant, TBI, intracranial hemorrhage

Oral anticoagulant and antiplatelet are often prescribed in clinical practice. These drugs are mainly consumed by geriatric patients to prevent or treat cerebrovascular, systemic embolism, or heart condition. Managing anticoagulated TBI patients is a challenging task for surgeons. This study aims to review available literatures regarding anticoagulated TBI patients and to suggest a treatment algorithm for such cases. Based on several retrospective and prospective studies, it might be wasteful to do a routine follow-up CT scan on anticoagulated TBI patients. The risk of new lesion development or presenting lesion progression seems to be especially low among patients with negative initial CT scan. We suggest to reserve repeat CT scan for patients with evident neurological deterioration. Tighter observation for anticoagulated patients with positive initial CT scan might be useful. Anticoagulation reversal is recommended by the American College of Cardiology, but some studies reported that reversal should be directed by INR. Acute antiplatelet cessation is still controversial for aspirin, but it is advised for clopidogrel. Preoperative management of both anticoagulant and antiplatelet should take into account the bleeding risk of the surgical procedure. Blind cessation and reversal of anticoagulant and/or antiplatelet might delay the timing of surgery and thus would better be avoided.

Introduction

Traumatic brain injury (TBI) accounts for around 9% of global mortality (Hutchinson, 2019) and disability (Silver, J. & Ziejewski, M. North, 2018). The burden of TBI also affects elderly population due to global increase in life expectancy.³ The elderly in general is more prone to traumatic brain injury (TBI) and traumatic intracranial hemorrhage due to age-related anatomical changes (Scotti, 2019). The prevalent consumption of anticoagulant and/or antiplatelet consumption among this population might further complicate things (Andreotti, F. 2015). Anticoagulant and antiplatelet are intended to prevent or treat cerebrovascular, systemic embolism, or heart condition (Prexl, 2018). Patients on anticoagulant or antiplatelet are at risk for hemorrhagic events following trauma and higher risk of mortality in traumatic brain injury (TBI) cases (Mina, 2002).
Managing anticoagulated TBI patients demands judicious weighing of the risk of catastrophic bleeding during and after surgery against the risk of thromboembolic events (Patel, R. B. 2019). Continuing the agents might make the surgeon wary of excessive bleeding during the procedure, while stopping the agents put the patients at risk of unwanted thromboembolic complication. This study aims to review available literatures regarding anticoagulated TBI patients and to suggest a treatment algorithm for such cases.

**Type of Anticoagulants**

*Vitamin K antagonist*

Vitamin K antagonist (VKA) such as warfarin is among the most widely used anticoagulants (Palaiodimos, 2019 and Barnes, G. D. 2015). VKA lessen the availability of vitamin K, thus affecting the production of vitamin K-dependent coagulation factors, namely factor II, VII, IX, and X (Figure 1) (Baglin, T, 2013). Warfarin dosing is challenging due to its narrow therapeutic index and inter-individual variability (Kearon, C. 2016). Warfarin could be prescribed with antiplatelet agents such as aspillet, clopidogrel, or both for patients with heart condition (Sorensen, R., 2019). Warfarin has been associated with incident of spontaneous intracerebral hemorrhage (Hart, R., Boop, B. & Anderson, 1995).

*Non-Vitamin K Antagonist Oral Anticoagulant*

Non-vitamin K antagonist oral anticoagulant (NOAC) works by directly inhibiting thrombin or factor X (Figure 1) (Wang, Y. & Bajorek, B, 2014). The first NOAC to be approved by the United States’ Food and Drug Administration (FDA) was Dabigatran in 2010 (Ashrafi, F., 2017). Dabigatran at 110 mg provided similar efficacy with that of warfarin in preventing stroke and systemic embolism, but with lower rates of major hemorrhagic complication (Connolly, S. J., 2009). Others NOACs such as rivaroxaban (Patel, M. R, 2019), apixaban (Granger, C. B, 2019), and edoxaban (Giugliano, R. P., 2013) then were also proven to be as effective as warfarin yet with less risk of adverse bleeding.

*Unfractionated Heparin and Low molecular weight heparin*

Low-molecular weight heparin (LMWH) such as enoxaparin is a class of anticoagulant which inactivates thrombin and factor X through an antithrombin-
dependent mechanism (Figure 1). Although its mechanism of action is similar to unfractionated heparin (UFH), LMWH is associated with less adverse effects (Alikhan, R., 2014; Barrera, L. M., 2013; Kahn, S. R., 2012).

Both UFH and LMWH are used to treat systemic thromboembolism (Hirsh, J. 2001) and acute coronary syndrome (Roffi, M., 2015). However, LMWH is available for outpatient setting in the form of subcutaneous injection and oral regiment while UFH is given intravenously. UFH is dosed on a case-by-case manner due to inter-individual difference of anticoagulant response to this drug. Monitoring of activated thromboplastin time (APTT) is advised for UFH administration.

Indirect Xa Inhibitor

This class of anticoagulant inhibits factor Xa through the help of antithrombin (AT) as co-factor (Figure 1) (Rupprecht, H. J. 2010). Indirect Xa inhibitor like Fondaparinux has been proven effective for patients with acute coronary syndrome or for deep vein thrombosis (DVT) prevention after major orthopedic surgery (Yusuf, S., 2011).

Anticoagulants and Risk of Traumatic Intracranial Hemorrhage

Various studies on anticoagulant/antiplatelet effect on traumatic intracranial hemorrhage have been published (Table 1). Patients on anticoagulant and/or antiplatelet should have had higher risk of developing intracranial hemorrhage, yet published studies showed conflicting results.

Clopidogrel has been associated with at least similar risks of bleeding with warfarin in several published studies. Nishijima et al. reported that patients on clopidogrel (12%; CI 95% 8.4-16.4%) is at higher risk of intracranial hemorrhage compared with those on warfarin (5.1%; CI 95% 3.6-7.0%). Patients on clopidogrel is 2.3 times (95% CI 1.48-3.63) more likely to suffer from intracranial bleeding (Nishijima, D. K., 2012). Moustafa et al. studied 293 TBI cases who were on antiplatelet agents and found that most patients with intracranial hemorrhage consumed aspirin (65.4%). This finding, however, is not statistically significant when compared with those consuming the same drug yet without any intracranial lesion (p = 0.31). Aspillet + clopidogrel in this study was found to be significant factor to the incident of traumatic intracranial hemorrhage (p = 0.04) (Moustafa, F., 2018).

In a study on 206 anticoagulated TBI cases, Cipriano et al. found 23 cases with intracranial hemorrhage, 19 of whom were on warfarin. The other four were on NOAC. In contrast, Jentzch et al. didn’t find a significant difference between patients on VKA and those on NOAC (Jentzch, T., 2015). Dunham et al. found that intracranial hemorrhage incident between patients on anticoagulant and/or antiplatelet was not statistically different from those not on any medications (p=0.32). Warfarin, known for its hemorrhagic complication, was also not significantly different from non-medicated subjects (p=0.83) (Dunham, C. M., 2014). According to Riccardi et al., warfarin yield higher rate (10.16%) of traumatic intracranial hemorrhage compared with NOACs (10.6% vs 2.8%; p < 0.05) (Riccardi, A., 2017).

Nishijima published yet another study in 2017 regarding out-of-hospital triage on adults with head injury. Of 2110 patients, 566 were on anticoagulant or antiplatelet. Fifty two of them were diagnosed with traumatic intracranial hemorrhage. In total, there were 137 subjects who were on warfarin, 303 on aspirin, 12 on NOACs, 71 on other classes of antiplatelet, and 72 on more than one type of medications. However it was not clear which medication dominated those 52 who were diagnosed with traumatic intracranial hemorrhage (Nishijima, D. K., 2017).

Inamasu et al. reported that among 82 patients with traumatic intracranial
hemorrhage, 37 (45.1%) was on anticoagulant or antiplatelet. The authors unfortunately did not specifically mention which agents were consumed by the subjects. This study found that poor Glasgow Outcome Scale (GOS) was more common in the oldest subgroup (≥ 85 yo), despite not statistically significant (p = 0.37) (Inamasu, J., 2010). Nishijima et al. in 2013 published a cohort study on 77 TBI patients, 27 of whom were on warfarin or clopidogrel. On 6-month-follow-up, unfavorable outcome was more prevalent among the warfarin/clopidogrel cohort. Similarly, Powers et al. and Won et al. also found that antiplatelet/anticoagulant consumption was positively correlated with death (OR 2.71, p < 0.001) and unfavorable outcome at discharge (Won, S. Y., 2017), respectively.

### Table 1: Studies reporting on proportion of anticoagulated TBI patients who developed intracranial hemorrhage upon presentation

| Authors                | Study Type | (n) of Cases | n(%) of Intracranial Hemorrhage | Causative Agent | Initial GCS | (n) of Surgery |
|------------------------|------------|--------------|---------------------------------|-----------------|-------------|---------------|
| Jentzch et al.          | Retrospective | 69           | 19 (27.5)                      | Rivaroxaban, Phenprocoumon | 15          | 9             |
| Cipriano et al.         | Prospective | 206          | 23 (11.2)                      | Warfarin        | 13-15       | 0             |
| Nishijima et al., 2012  | Prospective | 1064         | 70 (6.5)                       | Clopidogrel     | <8-15       | 24            |
| Chenoweth et al.        | Retrospective | 33           | 1 (3)                          | Dabigatran      | 14-15       | 0             |
| Dunham et al.           | Retrospective | 198          | 72 (36.4)                      | Aspirin, Clopidogrel | <12-15     | n/a           |
| Rendell and Batchelor   | Retrospective | 82           | 12 (15)                        | Warfarin        | <8-15       | 8             |
| Mina et al.             | Prospective | 94           | 25 (27)                        | Warfarin        | 14 ± 2.9    | n/a           |
| Brewer et al.           | Retrospective | 141          | 41 (29)                        | Warfarin, Clopidogrel, Aspirin | 15       | 5             |
| Riccardi et al.         | Prospective | 225          | 15 (6.7)                       | Warfarin        | 14-15       | 0             |
| Siracuse et al.         | Prospective | 5371         | 526 (9.7)                      | Warfarin, Clopidogrel | n/a     | n/a           |
| Fabbri et al.           | Retrospective | 1366         | 180 (13.2)                     | Aspirin, Ticlopidine, Indobufen | 14-15     | n/a           |
| Moustafa et al.         | Retrospective | 293          | 26 (8.9)                       | Aspirin         | 13-15       | 6             |
| Nishijima et al., 2017  | Retrospective | 566          | 52 (9)                         | n/a             | n/a         | 9             |

*Only anticoagulated TBI cases

*Agents which cause the most/the most statistically significant incident of traumatic intracranial hemorrhage within the respective study

Further studies to evaluate the risk of traumatic intracranial hemorrhage among anticoagulated patients are warranted. At the moment, warfarin and clopidogrel seems to be the most common causative drugs in such cases. These two agents also seems to be the most-studied ones. TBI patients who are on anticoagulant are prone to unfavorable outcome.

**Anticoagulants and Risk of Traumatic Intracranial Hemorrhage Progression**

There have been conflicting results on anticoagulant or antiplatelet effects on the...
progression of intracranial hemorrhage (Table 2). Anticoagulated, non-traumatic patients were reported to have higher risk of expanding intracerebral hemorrhage (ICH) compared with those not on anticoagulant (Flibotte, J. J, 2004).

Ivascu et al. retrospectively studied 109 patients with pre-injury antiplatelet regimen. In this study, initial CT finding is divided into four grades, they are minimal (grade I), moderate (grade II), severe (grade III), and moribund hemorrhage (grade IV). This study found that the majority of patients had grade I (64.2%) and grade II (15.6%) hemorrhagic lesion on initial CT. Grade III and grade IV lesion on initial CT was found in only 9.2% and 11% of patients, respectively. Eighty one grade I and grade II patients were re-scanned and four (3.6%) patients showed progressing lesion (Ivascu, F. A. 2008).

Huang et al. 2019 published a retrospective study on 232 TBI patients who consumed warfarin with presenting GCS of 13-15. All patients had no intracranial lesion upon admission, but 4 patients (1.7%) were found to develop delayed intracranial hemorrhage within the first 24 hours. Two patients had subarachnoid hemorrhage on the follow-up CT scan, one patient had punctate hemorrhage, and one patient had interhemispheric subdural hematoma.

A prospective study by Menditto et al. found that 5 of 97 minor head injury patients with normal initial CT scan developed new hemorrhagic lesion on follow-up CT within the first 24 hours. However, only one of them required surgical intervention. Another two patients with two normal CTs were admitted few days later with symptomatic subdural hematoma (SDH) although none required surgery. Both patients had international normalized ratio (INR) of > 3 (Menditto, V. G. 2012).

A retrospective study on 234 patients on various anticoagulant or antiplatelet found that repeat CT found new hemorrhagic lesion in only two (0.85%) patients. Both patients were on dual antiplatelet therapy without anticoagulant (Scantling, D. 2017).

Joseph et al. revealed an interesting finding through two separated publications. The first study found that there were no statistical differences between TBI patients on aspirin than those not on any antiplatelet. However, the second study reported that almost all TBI patients on clopidogrel suffered from intracranial hemorrhage progression upon repeat CT (Joseph, B. 2014).

In spite of the reported safety of NOACs Zeeshan et al. presented a contradicting result. In a comparison study between NOACs and warfarin, the authors found that progressing lesion is more common in NOACs than in warfarin group (26% vs 13%, p = 0.03). Worsening lesion in NOACs group also required more neurosurgical interventions (20% vs 9.2%, p = 0.04) (Zeeshan, M., 2013).

In a study by Parra et al., dabigatran causes 4 of 5 patients to suffer from deteriorating intracranial bleeding. That said, all of those five also consumed warfarin, aspirin, or clopidogrel. Eleven of twenty five patients who consumed rivaroxaban and apixaban in this study also experienced progressing lesion (Parra, M. W, 2013). That said, Feeney et al. found that NOACs in general yield significantly lower mortality (4.9% vs. 20.8%; p < 0.008) and lower rate of surgery (8.2% vs. 26.7%; p = 0.023) than warfarin (Feeney, J. M., 2016).
Table 2: Studies on progression/development of intracranial hemorrhagic lesion among TBI patients with anticoagulant and/or antiplatelet

| Authors            | Study          | Agents            | (n) of Cases* | (n) of Surgery | Initial GCS | New/Progressing Lesion on Follow-up CT n(%) |
|--------------------|----------------|-------------------|---------------|---------------|-------------|-------------------------------------------|
| **Studies with Unremarkable Initial CT Scan** |
| Huang et al.       | Retrospective  | VKA               | 232           | 0             | 13-15       | 4 (1.7)                                   |
| Menditto et al.    | Prospective    | VKA               | 97            | 1             | 14-15       | 7 (7.2)                                   |
| Scantling et al.   | Retrospective  | VKA, NOAC, AP     | 234           | 0             | 15          | 2 (0.85)                                  |
| Kaen et al.        | Prospective    | VKA, AP           | 137           | 0             | 14-15       | 2 (1.4)                                   |
| Barmparas et al.   | Retrospective  | NOAC, AP          | 249           | 0             | < 8-15      | 2 (0.8)                                   |
| Peck et al.        | Retrospective  | VKA, AP, LMWH     | 424           | 0             | 14.8 ± 0.9  | 4 (0.9)                                   |
| **Studies with Remarkable Initial CT Scan** |
| Ivascu et al.      | Retrospective  | AP                | 109           | n/a           | 13.6 ± 2.8  | 4 (3.6)                                   |
| Beynon et al.      | Retrospective  | VKA, NOAC         | 128           | 83            | 9-15        | 23 (17.9)                                 |
| Jentzch et al.     | Retrospective  | VKA, NOAC         | 69            | 9             | 15          | 5 (5.7)                                   |
| Cipriano et al.    | Prospective    | VKA, NOAC         | 206           | 0             | 13-15       | 3 (1.5)                                   |
| Nishijima et al., 2010 | Retrospective  | VKA               | 40            | 11            | 12-15       | 7 (17.5)                                  |
| Nishijima et al., 2012 | Prospective    | VKA, AP           | 1064          | 24            | <8-15       | 4 (0.37)                                  |
| Joseph et al., 2014 | Prospective    | AP                | 72            | 4             | <8-15       | 18 (25)                                   |
| Joseph et al., 2014 | Prospective    | AP                | 71            | 7             | <8-15       | 65 (91.5)                                 |
| Deloughery et al.  | Retrospective  | VKA               | 54            | n/a           | ±10         | 15 (27.7)                                 |
| Zeeshan et al.     | Prospective    | VKA, NOAC         | 210           | 27            | 8-15        | 36 (17.1)                                 |
| Oyama et al.       | Retrospective  | VKA               | 25            | 5             | 13 ± 2.4    | 4 (20)                                    |
| Parra et al.       | Retrospective  | VKA, NOAC         | 45            | n/a           | ±14         | 11 (24.4)                                 |
| Pruitt et al.      | Retrospective  | VKA, AP           | 644           | 99            | 13-15       | 45 (7)                                    |

*The number shown represents patients who are on anticoagulant and/or antiplatelet.

Based on several retrospective and prospective studies on table 1, it might be wasteful to do a routine follow-up CT scan on anticoagulated TBI patients. The risk of new lesion development or presenting lesion progression seems to be especially low among patients with negative initial CT scan. We suggest to reserve repeat CT scan for patients with evident neurological deterioration. Tighter observation for anticoagulated patients with positive initial CT scan might be useful.

**Reversing Anticoagulants and Perioperative Management**

Upon receiving TBI patients with known history of anticoagulant and/or antiplatelet, it is important to know if their hemostatic function is within physiologic limit. Guidelines on how and when to reverse anticoagulant are available,
although none is specifically related to trauma cases.

The American College of Cardiology’s (ACC) consensus suggests that bleeding at critical site, including intracranial, should prompt cessation of any anticoagulant. Bleeding which causes hemodynamic instability, hemoglobin (Hb) drop of ≥ 2 g/dL, or the need of ≥ 2 unit of red blood cells (RBC) are also considered major (Tomaselli, G. F. 2017).

Thrombocytopenia or other pro-hemorrhagic condition should be tackled prior to administering reversal agents (Table 3). If the patients are on VKA, 5-10 mg of Vitamin K should immediately be injected. Interestingly, ACC put surgical procedure before reversing anticoagulated state if the patients are in dire need of the said procedure.

In general, prothrombin time (PT) and/or an activated partial thromboplastin time (aPTT) should be checked in all anticoagulated patients. PT and INR are recommended for patients taking VKA. INR is also used to guide reversal agent dosing. Patients taking dabigatran ideally require more sophisticated lab indicators, such as dilute thrombin time, ecarin clotting time, and ecarin chromogenic assay. However, these examinations are not readily available in many hospitals, thus thrombin time (TT) and aPTT should be requested. The ideal assessment for rivaroxaban, apixaban, and edoxaban is chromogenic anti-Xa assay. As this is also not widely available, PT can be requested instead.67 Repeat INR testing within 15-60 minutes of PCC administration and serially every 6-8 hours for the next 24-48 hours are recommended (Frontera, J. A. 2016).

| Table 3 Assessment of VKA and NOACs and their reversal agent (Tomaselli, G. F. 2017) |
|------------------------------------------|------------------------------------------|------------------------------------------|
| **VKA**                                | **NOAC**                                | **Dabigatran**                           |
| Monitor INR and aPTT                    | Monitor TT and aPTT                      | Idarucizumab 5 mg IV                     |
| 4F-PCC                                  |                                          | OR                                       |
| • INR 2-4 → 25 u/kg                     |                                          | 4F-PCC 50 u/kg IV                       |
| • INR 4-6 → 35 u/kg                     |                                          | OR                                       |
| • INR > 6 → 50 u/kg                     |                                          | 4F-PCC 50 u/kg IV                       |
| **OR**                                  |                                          | OR                                       |
| 4F-PCC                                  |                                          | aPCC 50 u/kg IV                         |
| • 1000 u for any major bleed            |                                          | If patient is known to have recently    |
| • 1500 u for intracranial hemorrhage    |                                          | ingested the drug (2-4 hours), oral     |
| **OR**                                  |                                          | activated charcoal could be considered   |
| FFP 10-15 ml/kg                         |                                          | If patient is known to have recently    |
|                                         |                                          | ingested the drug(s) (2-4 hours), oral   |
|                                         |                                          | activated charcoal could be considered   |

4F-PCC: Four-factor prothrombin complex concentration
aPCC: activated prothrombin complex concentration

Keeling et al. published a paper on how to stop anticoagulants perioperatively (Table 4). Should surgery be needed promptly, VKA can be stopped immediately. The cessation of NOACs is more complicated as creatinine clearance need to be calculated prior to halting the agents. If the surgery is a major procedure with high bleeding risk, the gap between stopping the medication to the surgery is also longer (Keeling, D. 2016).
Table 4 Recommendation on pre-operative anticoagulant management

|                  | Pre-Emergency | Pre-Elective               |
|------------------|---------------|---------------------------|
| **VKA**          |               |                           |
| Stop immediately |               |                           |
| Vit. K 5 mg IV   |               | Stop 5 days prior to procedure |
| OR               |               |                           |
| 4F-PCC according to INR |       |                           |

| Cr. Clearance (ml/min) | Low Bleeding Risk (h) | High Bleeding Risk (h) |
|-----------------------|-----------------------|------------------------|
| **Dabigatran**        |                       |                        |
| ≥ 80                  | 24                    | 48                     |
| ≥ 50 - < 80           | 24-48                 | 48-72                  |
| ≥ 30 - < 50           | 48-72                 | 96                     |
| **Rivaroxaban**       |                       |                        |
| ≥ 30                  | 24                    | 48                     |
| < 30                  | 48                    | 72                     |
| **Apixaban**          |                       |                        |
| ≥ 30                  | 24                    | 48                     |
| < 30                  | 48                    | 72                     |
| **Edoxaban**          |                       |                        |
| ≥ 30                  | 24                    | 48                     |

Patients who are long-term consumer of VKA can be candidate for bridging therapy. Bridging therapy refers to administering alternative anticoagulants who are more short-acting around the time of scheduled surgery. The notion behind this strategy is to minimize the risk of operative bleeding while also mitigating the risk of systemic thromboembolism, although some studies on did not show fully favorable outcome bleeding-wise (Eijgenraam, P., 2013).

Table 5 Consideration for bridging therapy

| Conditions | Consideration                                                                 |
|------------|-------------------------------------------------------------------------------|
| **VTE**    | VTE within the previous 3 months                                               |
|            | Patients who previously suffered from VTE despite being on therapeutic anticoagulation, who now have a target INR of 3.5 |
| **AF**     | Patients with previous stroke/TIA in the last 3 months                         |
|            | CHADS₂ score of 5-6                                                           |
|            | (Patients with previous stroke/TIA + 3 or more of the followings: )            |
|            | • Congestive heart failure                                                     |
|            | • Hypertension (> 140/90 mmHg on medication)                                   |
|            | • Age ≥ 75 yo                                                                  |
|            | • Diabetes mellitus                                                           |
| **MHV**    | MHV other than those with a bileaflet aortic valve and no other risk factors  |

VTE: Venous thromboembolism
INR: International Normalized Ratio
AF: Atrial Fibrillation
TIA: Transient Ischemic Attack
CHADS score: Congestive heart failure, Hypertension, Age ≥ 75 yo, Diabetes, Stroke
MHV: Mechanical Heart Valve
There is no obligation to stop antiplatelet, more so if the patient is on aspirin monotherapy. However, it is advised to stop aspirin 3 days before to 7 days after a surgery with high bleeding risk. Intravenous tranexamic acid could be administered prior to high bleeding risk surgery. Platelet transfusion should be reserved for when tranexamic acid is deemed inadequate to stop peri- or post-operative bleeding, and when there is no adequate time to properly stop the drugs. Platelet transfusion is best given two hours after last aspirin ingestion or > 12-24 hour after last clopidogrel ingestion. General recommendation for peri-operative antiplatelet management in elective cases can be seen on Table 6.

### Table 6 General recommendation for pre-operative antiplatelet cessation

| Agents  | Low Risk Bleeding | High Risk Bleeding |
|---------|-------------------|--------------------|
| Aspirin | Continue          |                    |
|         | Elective          |                    |
|         | • Stop -3 to +7 days if antiplatelets is for secondary prevention of cardiovascular disease |
|         | • Continue if patients had recent ACS (surgery should be deferred if possible) |
|         | • Continue if surgery can’t be postponed, but clopidogrel should be stopped Emergent |
|         | • Tranexamic acid ± Platelet transfusion |
| Clopidogrel | Continue |                    |
|         | Elective          |                    |
|         | • Continue if patients had recent ACS (surgery should be deferred if possible) |
|         | • Stop -5 days if surgery can’t be postponed Emergent |
|         | • Tranexamic acid ± Platelet transfusion |

Aggressive warfarin reversal protocol has reduced mortality from 50% to 10% in a study. Although it is recommended to stop and reverse anticoagulant before surgery, a study found that thromboembolic complication did not significantly differ between reversed and non-reversed cohorts despite the former achieved normal INR earlier. The reversal agent used in this study was recombinant activated factor VIIa (rFVIIa) (Nishijima, D. K., 2010). rFVIIa also did not yield better outcome, although it was reportedly effective to normalize INR. INR was significantly decreased using human factor IX complex, fresh frozen plasma, and/or vitamin K in another study (Oyama, H. 2013).

In a retrospective study, INR of 2-3 (therapeutic range) seemed to be safe among TBI cases. Interestingly, INR of < 2 (subtherapeutic range) has a relative risk of 1.89 (95% CI 0.65 to 5.55) for intracranial hemorrhage. Similarly, Brewer et al. reported that the mean INR of patients with intracranial hemorrhage was lower than those without intracranial hemorrhage (1.97 ± 0.92 vs 2.3 ± 1.2; (p 0.0987)). Franko et al. retrospectively analyzed 1,493 TBI cases and revealed that ICH and mortality were more prevalent with higher INR especially at a value of > 4 (Franko, J., 2006).

Medium elevation of INR equals modest deficiency of clotting factors, thus any efforts to further lower it might not be fruitful. Plasma transfusion to achieve normal INR might also delay surgery. Nevertheless, in 2016 Frontera et al. published a guideline for antithrombotics reversal in intracranial hemorrhage, in which reversal for patients with INR ≥ 1.4 is advised. Reversal within first 10 hours results in less risk of intracranial hemorrhage progression according to a small study (Andrews, H. 2017).
Proposed Algorithm

Although our literature review mainly consist of low-quality evidence, important points can be noted to construct an algorithm for anticoagulated TBI patients with intracranial hemorrhage. Figure 2 illustrate our proposed algorithm.

The presence of intracranial lesion after traumatic events is the first factor to consider before proceeding to further treatment. If intracranial lesion is found, the next step is to decide if it is bound for surgery. The absence of intracranial lesion or surgical indication warrants 24-hours observation. Should neurological deterioration occurs during observation, repeat CT scan is recommended.

The type of anticoagulant should first be identified before proceeding to surgery. VKA consumption should be stopped and IV vitamin K should be administered. There is no agreed value of INR on which anticoagulant reversal should be performed. At the moment, we suggest a cut-off point of 1.4 as a guide to reverse anticoagulant. The next step is to identify whether the patient is on antiplatelet. Available evidence suggest that clopidogrel has to be discontinued. Tranexamic acid is recommended for patients who are on antiplatelet, while platelet transfusion should be selectively transfused.

Figure 2. Proposed algorithm of anticoagulated TBI patients
References

Albers, G. W., Sherman, D. G., Gress, D. R., Paulseth, J. E. & Petersen, P. Stroke prevention in nonvalvular atrial fibrillation: A review of prospective randomized trials. Ann. Neurol. 30, 511–518 (1991).

Alikhan, R., Bedenis, R. & Cohen, A. T. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2014, (2014).

Andreotti, F. et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 36, 3238–3249 (2015).

Andrews, H., Rittenhouse, K., Gross, B. & Rogers, F. B. The Effect of Time to International Normalized Ratio Reversal on Intracranial Hemorrhage Evolution in Patients with Traumatic Brain Injury. J. Trauma Nurs. 24, 381–384 (2017).

Ashrafi, F., Rezaie, N. & Mousavi, S. New indications for dabigatran: A suggestion from a drug use evaluation study. J. Res. Pharm. Pract. 6, 211 (2017).

Baglin, T. et al. Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 11, 756–760 (2013).

Barmparas, G. et al. The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study. Am. J. Surg. 217, 1051–1054 (2019).

Barnes, G. D., Ageno, W., Ansell, J. & Kaatz, S. Recommendation on the nomenclature for oral anticoagulants: Communication from the SSC of the ISTH. J. Thromb. Haemost. 13, 1154–1156 (2015).

Barnes, G. D., Lucas, E., Alexander, G. C. & Goldberger, Z. D. National trends in ambulatory oral anticoagulant use. Am. J. Med. 128, 1300-1305.e2 (2015).

Barrera, L. M. et al. Thromboprophylaxis for trauma patients. Cochrane Database of Systematic Reviews 2013, (2013).

Bauer, K. A., Eriksson, B. I., Lassen, M. R. & Turpie, A. G. G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N. Engl. J. Med. 345, 1305–1310 (2001).

Beynon, C. et al. Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants. Neurocrit. Care 30, 322–333 (2019).

Brewer, E. S. et al. Incidence and predictors of intracranial hemorrhage after minor head trauma in patients taking anticoagulant and antiplatelet medication. J. Trauma 70, E1–E5 (2011).

BRIDGE Study Investigators. Bridging Anticoagulation. Circulation 125, (2012).

Chenoweth, J. A., Johnson, M. A., Sutter, M. E., Nishijima, D. K. & Holmes, J. F. Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health Prevalence of Intracranial Hemorrhage after Blunt Head Trauma in Patients on Pre-injury
Dabigatran. West. J. Emerg. Med. 18, (2017)

Cipriano, A. et al. Intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: significant differences between direct oral anticoagulants and vitamin K antagonists European Federation of Neurological Societies. Intern. Emerg. Med. (2018). doi:10.1007/s11739-018-1806-1

Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).

Davis, J. W. et al. Placement of intracranial pressure monitors: Are ‘normal’ coagulation parameters necessary? J. Trauma - Inj. Infect. Crit. Care 57, 1173–1177 (2004).

Deloughery, E. P., Lenfesty, B. & Deloughery, T. G. The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: A retrospective case-control study. Blood Coagul. Fibrinolysis 24, 317–320 (2013).

Dunham, C. M. et al. Traumatic Intracranial Hemorrhage Correlates with Preinjury Brain Atrophy, but Not with Antithrombotic Agent Use: A Retrospective Study. PLoS One 9, (2014).

Eijgenraam, P., ten Cate, H. & Cate-Hoek, A. ten. Safety and Efficacy of Bridging with Low Molecular Weight Heparins: A Systematic Review and Partial Meta-Analysis. Curr. Pharm. Des. 19, 4014–4023 (2013).

Fabbri, A., Servadei, F., Marchesini, G., Stein, S. C. & Vandelli, A. Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. J. Neurol. Neurosurg. Psychiatry 81, 1275–1279 (2010).

Feeney, J. M. et al. Compared to warfarin, direct oral anticoagulants are associated with lower mortality in patients with blunt traumatic intracranial hemorrhage: A TQIP study. J. Trauma Acute Care Surg. 81, 843–848 (2016).

Flibotte, J. J., Hagan, N., O’Donnell, J., Greenberg, S. M. & Rosand, J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 63, 1059–1064 (2004).

Franko, J., Kish, K. J., O’Connell, B. G., Subramanian, S. & Yuschak, J. V. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J. Trauma - Inj. Infect. Crit. Care 61, 107–110 (2006).

Frontera, J. A. et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit. Care 24, 6–46 (2016).

Giugliano, R. P. et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 369, 2093–2104 (2013).

Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).

Hart, R., Boop, B. & Anderson, D. Oral Anticoagulants and Intracranial Hemorrhage. Facts and Hypotheses - PubMed. Stroke 26, 1471–7 (1995).

Hirsh, J., Anand, S. S., Halperin, J. L. & Fuster, V. Mechanism of Action and Pharmacology of Unfractionated Heparin. Arterioscler. Thromb. Vasc. Biol. 21, 1094–1096 (2001).
Holland, L. & Sarode, R. Should plasma be transfused prophylactically before invasive procedures? Current Opinion in Hematology 13, 447–451 (2006).

Holland, L. L. & Brooks, J. P. Toward Rational Fresh Frozen Plasma Transfusion The Effect of Plasma Transfusion on Coagulation Test Results. Am. J. Clin. Pathol. 126, 133–139 (2006).

Huang, J. L. et al. Evaluation of a protocol for early detection of delayed brain hemorrhage in head injured patients on warfarin. Eur. J. Trauma Emerg. Surg. 45, 481–487 (2019).

Hutchinson, P. J. et al. Consensus statement from the International Consensus Meeting on the Role of Decompressive Craniectomy in the Management of Traumatic Brain Injury: Consensus statement. Acta Neurochirurgica 161, 1261–1274 (2019).

Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 39, 119–177 (2018).

Inamasu, J. et al. Influence of age and anti-platelet/anti-coagulant use on the outcome of elderly patients with fall-related traumatic intracranial hemorrhage. Neurol. Med. Chir. (Tokyo). 50, 1051–1055 (2010).

Ivascu, F. A. et al. Predictors of mortality in trauma patients with intracranial hemorrhage on preinjury aspirin or clopidogrel. J. Trauma - Inj. Infect. Crit. Care 65, 785–788 (2008).

Jentzsch, T. et al. Is rivaroxaban associated with higher morbidity and mortality in patients with traumatic head injuries? A retrospective cohort study comparing rivaroxaban, no anticoagulation, and phenprocoumon. Clin. Neurol. Neurosurg. 169, 116–120 (2018).

Joseph, B. et al. Clinical outcomes in traumatic brain injury patients on preinjury clopidogrel: A prospective analysis. J. Trauma Acute Care Surg. 76, 817–820 (2014).

Joseph, B. et al. Low-dose aspirin therapy is not a reason for repeating head computed tomographic scans in traumatic brain injury: A prospective study. J. Surg. Res. 186, 287–291 (2014).

Kaen, A. et al. The value of sequential computed tomography scanning in anticoagulated patients suffering from minor head injury. J. Trauma - Inj. Infect. Crit. Care 68, 895–898 (2010).

Kahn, S. R. et al. Prevention of VTE in nonsurgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141, e195S-e226S (2012).

Kearon, C. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149, 315–352 (2016).

Keeling, D., Tait, R. C., Watson, H. & British Committee of Standards for Haematology. Peri-operative management of anticoagulation and antiplatelet therapy. British Journal of Haematology 175, 602–613 (2016).

McMillian, W. D. & Rogers, F. B. Management of prehospital antiplatelet and anticoagulant therapy in traumatic head injury: A review. J. Trauma - Inj. Infect. Crit. Care 66, 942–950 (2009).

Menditto, V. G., Lucci, M., Polonara, S., Pomponio, G. & Gabrielli, A. Management of minor head injury in patients receiving oral anticoagulant
therapy: A prospective study of a 24-hour observation protocol. Ann. Emerg. Med. 59, 451–455 (2012).

Mina, A. A. et al. Intracranial complications of preinjury anticoagulation in trauma patients with head injury. J. Trauma 53, 668–672 (2002).

Mina, A. A., Bair, H. A., Howells, G. A. & Bendick, P. J. Complications of preinjury warfarin use in the trauma patient. J. Trauma 52, 842–847 (2003).

Moustafa, F. et al. Predictive factors of intracranial bleeding in head trauma patients receiving antiplatelet therapy admitted to an emergency department. Scand. J. Trauma. Resusc. Emerg. Med. 26, (2018).

Nishijima, D. K. et al. Immediate and delayed traumatic intracranial hemorrhage in patients with head trauma and preinjury warfarin or clopidogrel use. Ann. Emerg. Med. 59, 460-468.e7 (2012).

Nishijima, D. K. et al. Out-of-Hospital Triage of Older Adults With Head Injury: A Retrospective Study of the Effect of Adding “Anticoagulation or Antiplatelet Medication Use” as a Criterion. Ann. Emerg. Med. 70, 127-138.e6 (2017).

Nishijima, D. K., Dager, W. E., Schrot, R. J. & Holmes, J. F. The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage. Acad. Emerg. Med. 17, 244–251 (2010).

Oyama, H. et al. Acute subdural hematoma in patients with medication associated with risk of hemorrhage. Neurol. Med. Chir. (Tokyo). 51, 825–828 (2011).

Palaiodimos, L. et al. Reversal of Novel Anticoagulants in Emergent Surgery and Trauma: A Comprehensive Review and Proposed Management Algorithm. Curr. Pharm. Des. 24, 4540–4553 (2018).

Parra, M. W. et al. Dabigatran bleed risk with closed head injuries: Are we prepared? J. Neurosurg. 119, 760–765 (2013).

Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).

Patel, R. B. & Tassiopoulos, A. K. Anticoagulants and Surgery: So Many Agents, So Many Taking Them. Adv. Surg. 53, 235–251 (2019).

Peck, K. A. et al. Delayed intracranial hemorrhage after blunt trauma: Are patients on preinjury anticoagulants and prescription antiplatelet agents at risk? in Journal of Trauma - Injury, Infection and Critical Care 71, 1600–1604 (J Trauma, 2011).

Powers, A. Y. et al. Predicting mortality in traumatic intracranial hemorrhage. J Neurosurg 132, 552–559 (2020).

Prexl, O. et al. The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old. Scand. J. Trauma. Resusc. Emerg. Med. 1–7 (2018).

Pruitt, P., Van Ornam, J. & Borczuk, P. A Decision Instrument to Identify Isolated Traumatic Subdural Hematomas at Low Risk of Neurological Deterioration, Surgical Intervention or Radiographic Worsening. Acad. Emerg. Med. 24, 1377–1386 (2017).

Rendell, S. & Batchelor, J. S. An analysis of predictive markers for intracranial haemorrhage in warfarinised head injury patients. Emerg. Med. J. 30, 28–31 (2013).

Riccardi, A. et al. Intracranial complications after minor head injury
(MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs). Am. J. Emerg. Med. 35, 1317–1319 (2017).

Roffi, M. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 37, 267–315 (2015).

Rupprecht, H. J. & Blank, R. Clinical pharmacology of direct and indirect factor xa inhibitors. Drugs 70, 2153–2170 (2010).

Scantling, D. et al. The role of delayed head CT in evaluation of elderly blunt head trauma victims taking antithrombotic therapy. Eur. J. Trauma Emerg. Surg. 43, 741–746 (2017).

Scotti, P. et al. Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes. J. Neurosurg. 1–10 (2019). doi:10.3171/2019.4.jns19252

Siegal, D. et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: Systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126, 1630–1639 (2012).

Silver, J. & Ziejewski, M. North American Brain Injury Society. J. Head Trauma Rehabil. 33, E67–E118 (2018).

Siracuse, J. J. et al. Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage. Surgery 148, 724–730 (2010).

Sørensen, R. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374, 1967–1974 (2009).

Tomaselli, G. F. et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J. Am. Coll. Cardiol. 70, 3042–3067 (2017).

Wang, Y. & Bajorek, B. New oral anticoagulants in practice: Pharmacological and practical considerations. American Journal of Cardiovascular Drugs 14, 175–189 (2014).

West, K. W., Adamson, C. & Hoffman, M. Prophylactic Correction of the International Normalized Ratio in Neurosurgery: A Brief Review of a Brief Literature. J Neurosurg 114, 9–18 (2011).

Won, S. Y. et al. Acute subdural hematoma in patients on oral anticoagulant therapy: Management and outcome. Neurosurg. Focus 43, 1–12 (2017).

Yusuf, S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354, 1464–1476 (2006).

Zeeshan, M. et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. in Journal of Trauma and Acute Care Surgery 85, 915–920 (Lippincott Williams and Wilkins, 2018).